2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE.
1. A compound of formula (I)
wherein
R 0 is selected from the group consisting of hydrogen, methyl, and CF 3 ;
R 1 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, trifluoromethyl, 2,2,2-trifluoroethyl, methoxy, ethoxy and methyl-carbonyl;
A 1 is selected from the group consisting of C 1-4 alkyl; wherein the C 1-4 alkyl is optionally substituted with one or more R X substituents;
wherein each R X is independently selected from the group consisting of hydroxy, oxo, C 1-8 alkyl, C 1-8 alkoxy, hydroxy substituted C 1-6 alkyl, amino substituted C 1-6 alkyl, cycloalkyl, cycloalkyl-C 1-4 alkyl-, biphenyl, aryl, C 1-4 aralkyl, heteroaryl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl-, spiro-heterocyclyl and —(C 1-4 alkyl) n -Q 2 -R 4 ;
wherein the R X cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl group, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, chloro, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, —C(O)O—(C 1-4 alkyl), hydroxy substituted C 1-4 alkyl, fluoro substituted C 1-4 alkyl, fluoro substituted C 1-4 alkoxy, 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein n is an integer from 0 to 1;
wherein Q 2 is selected from the group consisting of —O—, —S—, —C(O)—, —C(S)—, —C(O)O—, —OC(O)—, —NR G —, —NR G —C(O)—, —C(O)—NR G —, —NR G —SO 2 —, —SO 2 —NR G —, —NR G —SO—, —SO—NR G , —NR G C(O)O—, —OC(O)—NR G —, —O—SO 2 —NR G —, —NR G —SO 2 —O—, —NR G —C(O)—NR H , —NR G —C(S)—NR H — and —NR G —SO 2 —NR H —;
wherein each R G and R H is independently selected from the group consisting of hydrogen, C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 aralkyloxy substituted C 1-4 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the independently selected R G and R H cycloalkyl aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, —SO 2 —N(R J R K ), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein each R J and R K is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
wherein R 4 is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, fluoro substituted C 1-4 alkyl, cycloalkyl, aryl, biphenyl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the R 4 cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino and phenyl;
wherein the phenyl is optionally substituted with one or more substituent independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C(O)O—C 1-4 alkyl, C(O)—C 1-4 alkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino and —SO 2 —N(R E R F );
wherein each R E and R F is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
Q 1 is selected from the group consisting of —O—, —S—, —C(O)—, —C(S)—, —C(O)O—, —OC(O)—, —NR A —, —NR A —C(O)—, —C(O)—NR A —, —NR A C(S)—, —C(S)—NR A —, —NR A —SO 2 —, —SO 2 —NR A —, —NR A —SO—, —SO—NR A , —NR A —C(O)O—, —OC(O)—NR A —, —O—SO 2 NR A —, —NR A —SO 2 —O—, —NR A —C(O)—NR B —, —NR A —C(S)—NR B — and —NR A SO 2 —NR B —;
wherein each R A and R B is independently selected from the group consisting of hydrogen, C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 aralkyloxy substituted C 1-4 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl and spiro-heterocyclyl;
wherein the independently selected R A and R B cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, —SO 2 —N(R C R D ), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein each R C and R D is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
R 2 is selected from the group consisting of C 1-10 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the R 2 C 1-10 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)—C 1-4 alkyl, —C(O)—C 1-4 aralkyl, —C(O)O—C 1-4 alkyl, —C(O)O—C 1-4 aralkyl, —C 1-4 alkyl-C(O)O—C 1-4 alkyl, —C 1-4 alkyl-S—C 1-4 alkyl, —C(O)—N(R L R M ), —C 1-4 alkyl-C(O)—N(R L R M ), —NR L —C(O)C 1-4 alkyl, —SO 2 —N(R L R M ), —C 1-4 alkyl-SO 2 —N(R L R M ), C 1-6 alkyl, fluoro substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, carboxy substituted C 1-4 alkyl, C 1-4 alkoxy, —O—C 1-4 aralkyl, —O-(tetrahydropyranyl), —NH—C(O)—O—CH 2 -(tetrahydropyranyl), —N(CH 3 )—C(O)O—CH 2 -(tetrahydropyranyl), nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, phenyl, 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein the phenyl or tetrahydropyranyl is optionally substituted with one or more substituent independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, —O—C(O)—C 1-4 alkyl, —C 1-4 alkyl-OC(O)—C 1-4 alkyl, —O—C 1-4 aralkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino and di(C 1-4 alkyl)amino;
wherein each R L and R M is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
b is an integer from 0 to 1;
L 1 is selected from the group consisting of —O—, —S(O) 0-2 —, —NR N —, —C(O)—, —C(S)—, —C 1-4 alkyl-, -(hydroxy substituted C 1-4 alkyl)- and —(C 2-4 alkenyl)-;
wherein R N is selected from the group consisting of hydrogen and C 1-4 alkyl;
R 3 is selected from the group consisting of C 2-6 alkenyl, cycloalkyl, partially unsaturated carbocyclyl, aryl, biphenyl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the R 3 cycloalkyl, partially unsaturated carbocyclyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, halogen substituted C 1-4 alkyl, cyano substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halogen substituted C 1-4 alkoxy, nitro, cyano, —R 5 , —O—R 5 , —S—R 5 , —SO 2 —R 5 , —SO 2 —NR P —R 5 , —NR P —SO 2 —R 5 , —NH 2 , —N(R P )—R 5 , —C(O)—R 5 , —C(O)—NH 2 , —C(O)—NR P —R 5 , —NR P —C(O)—R 5 and —NR P —C(O)O—R 5 ;
wherein R 5 is selected from the group consisting of C 1-4 alkyl, aryl, C 1-4 aralkyl, partially unsaturated carbocyclyl, cycloalkyl, cycloalkyl-C 1-4 alkyl-, partially unsaturated carbocyclyl-C 1-4 alkyl-, heteroaryl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl and heterocyclyl-C 1-4 alkyl-;
wherein the R 5 aryl, partially unsaturated carbocyclyl, cycloalkyl, heteroaryl or heterocycloalkyl, whether alone or as part of a substituent group is optionally substituted with one or more substituent independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, halogen, hydroxy, carboxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano and nitro;
wherein each R P is selected from the group consisting of hydrogen, C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 aralkyloxy substituted C 1-4 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl and spiro-heterocyclyl;
wherein the R P cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, —SO 2 —N(R S R T ), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein each R S and R T is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
a is an integer from 0 to 3;
each R 10 is independently selected from the group consisting of hydroxy, halogen, C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkyl, halogen substituted C 1-4 alkoxy, —C(O)—NR V R W , —SO 2 NR V R W , —C(O)—C 1-4 alkyl and —SO 2 —C 1-4 alkyl;
wherein each R V and R V is independently selected from the group consisting of hydrogen and C 1-4 alkyl; alternatively R V and R W are taken together with the N atom to which they are bound to form a 5 to 6 membered saturated, partially unsaturated or aromatic ring structure;
provided that the halogens on the halogen substituted C 1-4 alkyl or the halogen substituted C 1-4 alkoxy are selected from the group consisting of chloro and fluoro;
or a pharmaceutically acceptable salt thereof.
2. A compound as in claim 1 wherein
R 0 is selected from the group consisting of hydrogen and methyl;
R 1 is selected from the group consisting of hydrogen, hydroxy, methyl, trifluoromethyl, methoxy and methyl-carbonyl;
A 1 is selected from the group consisting of C 1-4 alkyl; wherein the C 1-4 alkyl is optionally substituted with one to two R X substituents;
wherein each R X is independently selected from the group consisting of hydroxy, oxo, C 1-8 alkyl, C 1-8 alkoxy, hydroxy substituted C 1-4 alkyl, cycloalkyl, cycloalkyl-C 1-4 alkyl, biphenyl, aryl, C 1-4 aralkyl, heteroaryl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl-, spiro-heterocyclyl and —(C 1-4 alkyl) n -Q 2 -R 4 ;
wherein the R X cycloalkyl, aryl, heteroaryl or heterocycloalkyl group, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, chloro, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, hydroxy substituted C 1-4 alkyl, fluoro substituted C 1-4 alkyl, fluoro substituted C 1-4 alkoxy, 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein n is an integer from 0 to 1;
wherein Q 2 is selected from the group consisting of —O—, —C(O)—, —C(O)O—, —OC(O)—, —NR G —, —NR G —C(O)— and —C(O)—NR G —;
wherein R G is selected from the group consisting of hydrogen, C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 aralkyloxy substituted C 1-4 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl and C 1-4 aralkyl;
wherein the R G cycloalkyl, aryl, heteroaryl or heterocycloalkyl, whether alone or as part of a substituent group is optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, —SO 2 N(R J R K ), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein each R J and R K is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
wherein R 4 is selected from the group consisting of C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, fluoro substituted C 1-4 alkyl, cycloalkyl, aryl, biphenyl, heteroaryl, heterocycloalkyl and C 1-4 aralkyl;
wherein the R 4 cycloalkyl, aryl, heteroaryl or heterocycloalkyl, whether alone or as part of a substituent group is optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C(O)O—C 1-4 alkyl, C(O)—C 1-4 alkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino and phenyl;
wherein the phenyl is optionally substituted with one to two substituent independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino and di(C 1-4 alkyl)amino;
Q 1 is selected from the group consisting of —O—, —S—, —C(O)—, —C(S)—, —C(O)O—, —OC(O)—, —C(O)—NH—, —C(O)—N(CH 3 )—, —C(O)—N(CH 2 CH 3 )—, —C(O)—N(CH 2 CH 2 OH)—, —C(O)—N(C 1-4 alkyl))-, —C(O)—N(cycloalkyl)-, —C(O)—N(CH 2 CH 2 —O—C 1-4 aralkyl)-, —NH—, —N(C 1-4 alkyl)-, —NH—C(O)—, —N(C 1-4 alkyl)-C(O)—, —NH—C(O)O—, —N(C 1-4 alkyl)-C(O)O—, —NH—SO 2 —, —SO 2 —NH—, —NH—C(O)—NH—, NH—C(S)—NH— and —NH—SO 2 —NH—;
R 2 is selected from the group consisting of C 1-10 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, -heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the R 2 C 1-10 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)—C 1-4 alkyl, —C(O)—C 1-4 aralkyl, —C(O)O—C 1-4 alkyl, —C(O)O—C 1-4 aralkyl, —C(O)—N(R L R M ), —C 1-4 alkyl-C(O)O—C 1-4 alkyl, —C 1-4 alkyl-C(O)—N(R L R M ), —NR L —C(O)C 1-4 alkyl, C 1-6 alkyl, fluoro substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, carboxy substituted C 1-4 alkyl, C 1-4 alkoxy, —O—C 1-4 aralkyl, —O-(tetrahydropyranyl), —NH—C(O)—O—CH 2 -(tetrahydropyranyl), nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino phenyl and 5-tetrazolyl;
wherein the phenyl or tetrahydropyranyl is optionally substituted with one to two substituent independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —OC(O)—C 1-4 alkyl, —C 1-4 alkyl-OC(O)—C 1-4 alkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino and di(C 1-4 alkyl)amino;
wherein each R L and R M is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
b is an integer selected from 0 to 1;
L 1 is selected from the group consisting of —O—, —S(O)O 2 —, —C(O)—, —C(S)—, —C 1-4 alkyl- and (hydroxy substituted C 1-4 alkyl)-;
R 3 is selected from the group consisting of C 2-6 alkenyl, cycloalkyl, partially unsaturated carbocyclyl, aryl, C 1-4 aralkyl, biphenyl, heteroaryl and heterocycloalkyl;
wherein the R 3 cycloalkyl, partially unsaturated carbocyclyl, aryl, heteroaryl or heterocycloalkyl, whether alone or as part of a substituent group is optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, halogen substituted C 1-4 alkyl, cyano substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halogen substituted C 1-4 alkoxy, nitro, cyano, —R 5 , —O—R 5 , —C(O)O—R 5 and —SO 2 —NR P —R 5 ;
wherein R 5 is selected from the group consisting of C 1-4 alkyl, aryl, C 1-4 aralkyl, cycloalkyl and cycloalkyl-C 1-4 alkyl-;
wherein the R 5 aryl, whether alone or as part of a substituent group is optionally substituted with one to two substituent independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, halogen, hydroxy, carboxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano and nitro;
wherein R P is selected from the group consisting of hydrogen, C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 aralkyloxy substituted C 1-4 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl and C 1-4 aralkyl;
wherein the R P cycloalkyl, aryl, heteroaryl or heterocycloalkyl, whether alone or as part of a substituent group is optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, —SO 2 N(R S R T ), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein each R S and R T is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
a is an integer from 0 to 1;
R 10 is selected from the group consisting of hydroxy, halogen, C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkyl, halogen substituted C 1-4 alkoxy;
provided that the halogens on the halogen substituted C 1-4 alkyl and the halogen substituted C 1-4 alkoxy are selected from the group consisting of fluoro and chloro;
or a pharmaceutically acceptable salt thereof.
3. A compound as in claim 2 wherein
R 0 is hydrogen;
R 1 is hydrogen;
A 1 is selected from the group consisting of C 1-4 alkyl; wherein the C 1-4 alkyl is optionally substituted with one to two R X substituents;
wherein each R X is independently selected from the group consisting of C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, cycloalkyl, aryl, C 1-4 aralkyl, biphenyl, heterocycloalkyl, spiro-heterocyclyl and —(C 1-4 alkyl) n -Q 2 -R 4 ;
wherein the R X cycloalkyl or aryl, whether alone or as part of a substituent group is optionally substituted with one to two substituents independently selected from the group consisting of fluoro, chloro, hydroxy, oxo, C 1-4 alkyl and C 1-4 alkoxy;
wherein n is an integer from 0 to 1;
wherein Q 2 is selected from the group consisting of —C(O)—, —C(O)—NR G — and —NR G —C(O)—; wherein R G is selected from the group consisting of hydrogen and C 1-4 alkyl;
wherein R 4 is selected from the group consisting of cycloalkyl and heterocycloalkyl;
Q 1 is selected from the group consisting of —O—, —C(O)—, —C(O)O—, —C(O)—NH—, —C(O)—N(CH 3 )—, —C(O)—N(CH 2 CH 3 )—, —C(O)—N(CH 2 CH 2 OH)—, —C(O)—N(C 1-4 alkyl))-, —C(O)—N(cycloalkyl)-, —C(O)—N(CH 2 CH 2 —O—C 1-4 aralkyl)-, —NH—, —N(C 1-4 alkyl), —NH—C(O)—, —N(C 1-4 alkyl)-C(O)—, —NH—C(O)O—, —N(C 1-4 alkyl)-C(O)O—, —NH—SO 2 —, —NH—C(O)—NH— and NH—C(S)—NH—;
R 2 is selected from the group consisting of C 1-10 alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, C 1-4 aralkyl, heteroaryl, heterocycloalkyl, spiro-heterocyclyl and heteroaryl-C 1-4 alkyl-;
wherein the R 2 C 1-10 alkyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, whether alone or as part of a substituent group is optionally substituted with one to two substituent independently selected from the group consisting of C 1-5 alkyl, C 1-4 alkoxy, —O—C 1-2 aralkyl, —O-(tetrahydropyranyl), —NH—C(O)—O—CH 2 -(tetrahydropyranyl), halogen, trifluoromethyl, amino, cyano, hydroxy, oxo, carboxy, phenyl, —C(O)—C 1-4 alkyl, —C(O)O—C 1-2 aralkyl, —C(O)—N(R L R M ), —C(O)—N(C 1-4 alkyl)(cycloalkyl), —NH—C(O)—C 1-4 alkyl, —C(O)O—C 1-4 alkyl, —C 1-2 alkyl-C(O)O—C 1-4 alkyl, carboxy substituted C 1-2 alkyl and 5-tetrazolyl;
wherein the phenyl or tetrahydropyranyl is optionally substituted with one to two substituents independently selected from the group consisting of hydroxy, halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, hydroxy substituted C 1-2 alkyl, —OC(O)—C 1-2 alkyl, —C 1-2 alkyl-OC(O)—C 1-2 alkyl, amino, C 1-4 alkylamino and di(C 1-4 alkyl)amino;
wherein R L and R M are each independently selected from the group consisting of hydrogen, methyl and ethyl;
b is an integer from 0 to 1;
L 1 is selected from the group consisting of —O—, —C(O)—, —CH 2 — and —C(OH)—;
R 3 is selected from the group consisting of C 2-6 alkenyl, aryl, biphenyl, partially unsaturated carbocyclyl and heteroaryl;
wherein the R 3 aryl or heteroaryl group is optionally substituted with one to two substituents independently selected from the group consisting of hydroxy, halogen, C 1-4 alkyl, C 1-4 alkoxy, —S—C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, halogen substituted C 1-4 alkyl, —C(O)—NH 2 , —C(O)—C 1-4 alkyl, —NH—C 1-4 alkyl-cycloalkyl, —NH—C(O)—C 1-4 alkyl, —NH—C(O)—O—C 1-4 aralkyl, —SO 2 —NH—C 1-4 alkyl and —SO 2 —NH-phenyl;
a is an integer from 0 to 1;
R 10 is selected from the group consisting of halogen;
or a pharmaceutically acceptable salt thereof.
4. A compound as in claim 3 wherein
R 0 is hydrogen;
R 1 is hydrogen;
A 1 is selected from the group consisting of methyl, ethyl, 1-methyl-ethyl, (1)-(R)-methyl-ethyl, (1)-(S)-methyl-ethyl, 1-n-propyl-ethyl, (1)-(R)-n-propyl-ethyl, (1)-(S)-n-propyl-ethyl, 1-isopropyl-ethyl, (1)-(R)-isopropyl-ethyl, (1)-(S)-isopropyl-ethyl, 1-cyclohexyl-ethyl, (1)-(R)-cyclohexyl-ethyl, (1)-(S)-cyclohexyl-ethyl, 1-phenyl-ethyl, 1-(4-hydroxybenzyl)-ethyl, (1)-(R)-(4-hydroxybenzyl)-ethyl, (1)-(S)-(4-hydroxybenzyl)-ethyl, n-propyl, 1-hydroxymethyl-n-propyl, (1)-(R)-hydroxymethyl-n-propyl, (1)-(S)-hydroxymethyl-n-propyl, 1-(dimethyl)-n-propyl, 1-(n-propyl)-n-propyl, 1-isopropyl-n-propyl, (1)-(S)-isopropyl-n-propyl, (1)-(R)-isopropyl-n-propyl, 1-(n-pentyl)-n-propyl, 1-n-octyl-n-propyl, 1-cyclohexyl-n-propyl, (1)-(R)-cyclohexyl-n-propyl, (1)-(S)-cyclohexyl-n-propyl, 1-phenyl-n-propyl, 1-(4-chlorophenyl)-n-propyl, 1-(4-methylphenyl)-n-propyl, 1-(4-methoxyphenyl)-n-propyl, 1-(4-biphenyl)-n-propyl, 1-(N-piperidiny-carbonyl-n-propyl)-n-propyl, 1-(4-tetrahydropyranyl)-n-propyl, (1)-(R)-(4-tetrahydropyranyl)-n-propyl, (1)-(S)-(4-tetrahydropyranyl)-n-propyl, 1-(4-hydroxy-cyclohexyl)-n-propyl, 1-(N-methyl-N-cyclohexyl-aminocarbonyl)-n-propyl, (1)-(R)—(N-methyl-N-cyclohexyl-aminocarbonyl)-n-propyl, (1)-(S)—(N-methyl-N-cyclohexyl-aminocarbonyl)-n-propyl, 1-(1,4-dioxaspiro[4.5]decane)-n-propyl, (1)-(R)-(1,4-dioxaspiro[4.5]decane)-n-propyl, (1)-(S)-(1,4-dioxaspiro[4.5]dec-8-yl)-n-propyl, (1)-(R)-((4R)-hydroxycyclohexyl)-n-propyl, 1-(cylcohexan-4-one)-n-propyl, (1)-(R)-(cylcohexan-4-one)-n-propyl, (1)-(S)-(cylcohexan-4-one)-n-propyl, 1-pyranyl-n-propyl, (1)-(S)-pyranyl-n-propyl, n-butyl, 1-propyl-n-butyl, 1-phenyl-n-butyl, 1-(cyclohexylcarbonylaminomethyl)-ethyl, 1-(N-cyclohexyl-N-methyl-aminocarbonylethyl)-n-propyl, 1-(2-methyl-piperidinylcarbonyl-n-propyl)-n-propyl and 1-(4-methyl-piperidinylcarbonyl-n-propyl)-n-propyl;
Q 1 is selected from the group consisting of —O—, —C(O)—, —C(O)O—, —C(O)—NH—, —C(O)—N(CH 3 )—, —C(O)—N(CH 2 CH 3 )—, —C(O)—N(CH 2 CH 2 OH)—, —C(O)—N(isopropyl)-, —C(O)—N(cyclohexyl)-, —C(O)—N(CH 2 CH 2 —O-benzyl)-, —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —NH—C(O)—, —N(CH 3 )—C(O)—, —NH—C(O)O—, —N(CH 3 )—C(O)O—, —NH—SO 2 —, —NH—C(O)—NH— and NH—C(S)—NH—;
R 2 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, t-butyl, isobutyl, isopentyl, 3-n-heptyl, n-nonyl, amino-methyl, carboxy-methyl-, 2-amino-ethyl, 2-cyano-ethyl, 4-carboxy-n-butyl, 3-n-heptyl, 4-n-heptyl, 3-amino-n-propyl, 3,3,3-trifluoro-n-propyl, 3,3,3-trifluoro-isobutyl, 1-(1-carboxy-2-hydroxy-ethyl), 1-(S)-(1-carboxy-2-hydroxy-ethyl), 1-(R)-(1-carboxy-2-hydroxy-ethyl), 1-(1-carboxy-2-t-butoxy-ethyl), 1-(R)-(1-carboxy-2-t-butoxy-ethyl), 1-(1-carboxy-2-benzyloxy-ethyl), 1-(S)-(1-carboxy-2-benzyloxy-ethyl), 1-(R)-(1-carboxy-2-benzyloxy-ethyl), 1-(1-methoxy-carbonyl-2-benzyloxy-ethyl), 1-(S)-(1-methoxy-carbonyl-2-benzyloxy-ethyl), 1-(R)-(1-methoxy-carbonyl-2-benzyloxy-ethyl), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-phenyl-cyclopropyl, cyclopentyl-methyl, cyclopentyl-ethyl, 1-(1-aminocarbonyl-cyclopropyl), 4-hydroxy-cyclohexyl, 4-carboxy-cyclohexyl, cis-(4-carboxy)-cyclohexyl, trans-(4-carboxy)-cyclohexyl, 3-carboxy-cyclohexyl, cis-(3-carboxy)-cyclohexyl, 4-cyano-cyclohexyl, 4-methoxy-carbonyl-cyclohexyl, 3-methoxy-carbonyl-cyclohexyl, cis-(3-methoxy-carbonyl)-cyclohexyl, 4-ethoxy-carbonyl-cyclohexyl, (1)-(S)-((4R)-methoxy-carbonyl -cyclohexyl, (1)-(R)-((4S)-methoxy-carbonyl-cyclohexyl, 2-methyl-cyclohexyl, 4-methyl-cyclohexyl, 4-n-pentyl-cyclohexyl, 4-t-butyl-cyclohexyl, (1)-(S)-2-(R)-methyl-cyclopentyl, 3-methoxy-cyclohexyl, 1-(1-(4-chlorophenyl)-cyclopentyl), 4-trifluoromethyl-cyclohexyl, 4-oxo-cyclohexyl, 1-(4-benzyloxy-carbonyl-cyclohexyl), 1-(S)-(4-(S)-benzyloxy-carbonyl-cyclohexyl), 1-(4-amino-carbonyl-cyclohexyl), 1-(S)-(4-(S)-amino-carbonyl-cyclohexyl), 1-(4-methylamino-carbonyl-cyclohexyl), 1-(S)-(4-(S)-methylamino-carbonyl-cyclohexyl), 1-(4-(5-tetrazolyl)-cyclohexyl), phenyl, benzyl, phenyl-ethyl, 3-carboxy-methyl-benzyl, 3-methoxy-carbonyl -methyl-benzyl, 4-carboxy-phenyl, 3-cyano-phenyl, 4-methyl-phenyl, 4-t-butyl-phenyl, 4-n-butyl-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-dimethylamino-phenyl, 4-(methylcarbonylamino)-phenyl, 1-naphthyl-methyl, 1-(1,2,3,4-tetrahydro-naphthyl), 4-biphenyl, benzhydryl, 1-adamantyl, 2-adamantyl, 2-(R)-adamantyl, 2-(S)-adamantyl, N-piperidinyl, 1-(2-carboxy-piperidinyl), 1-(S)-2-carboxy-piperidinyl), 1-(2-methoxy-carbonyl-piperidinyl), 1-(S)-2-methoxy-carbonyl-piperidinyl), 1-(2-methyl-piperidinyl), 1-(4-methyl-piperidinyl), 1-(4-isopropyl-piperidinyl), 4-(1-methylcarbonyl)-piperidinyl), 3-(2,5-dimethyl-furyl), 4-tetrahydropyranyl, 4-(2-phenyl-thiazolyl)-methyl, 4-(1-phenyl-pyrazolyl)-methyl, 5-(3-methyl-isoxazolyl)-methyl, 3-(5-phenyl-isoxazolyl)-methyl, 1-(2-carboxy-pyrrolidinyl), 1-(S)-2-carboxy-pyrrolidinyl), 1-(2-(N-methyl-N-cyclohexylaminocarbonyl)-pyrrolidinyl), 1,4-dioxaspiro[4.5]dec-8-yl, 2-(bicyclo[2.2.1]heptyl), 1-(3-n-pentyl-bicyclo[2.2.2]-octyl, 2-bicyclo[2.2.2]octyl, 2-(R)-bicyclo[2.2.2]octyl, 2-(S)-bicyclo[2.2.2]octyl, 5-tetrazolyl-methyl, 2-imidazolyl-methyl, 5-imidazolyl-methyl, 4-pyridyl-methyl, 3-(1,2,4-triazolyl)-methyl, 1-(2-carboxy-octahydroindolyl), 1-(S)-2-carboxy-octahydroindolyl), 1-(2-methoxy-carbonyl-octahydroindolyl), 1-(S)-2-methoxy-carbonyl-octahydroindolyl), 2R-(3R,4S,5R-tri(methyl-carbonyloxy)-6R-(methyl-carbonyloxy-methyl)-tetrahydropyranyl)oxy-ethyl, 2R-(3S,4S,5R-trihydroxy-6R-(hydroxy-methyl)-tetrahydropyranyl)oxy-ethyl and 3-(2R-(3S,4S,5R,6R-tetrahydroxy-tetrahydropyrantl)-methoxy-carbonyl-amino)-n-propyl;
b is an integer from 0 to 1;
L 1 is selected from the group consisting of —O—, —C(O)—, —CH 2 — and —C(OH)—;
R 3 is selected from the group consisting of n-penten-1-yl, phenyl, 2-hydroxy-phenyl, 2-chloro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-fluoro-phenyl, 4-fluorophenyl, 2,6-difluoro-phenyl, 2-methyl-phenyl, 3-methyl-phenyl, 4-methyl-phenyl, 2-methoxy-phenyl, 4-methoxy-phenyl, 3,5-dimethoxy-phenyl, 2,6-dimethoxy-phenyl, 2-isopropyl-phenyl, 2-methylthio-phenyl, 2-fluoro-6-methoxy-phenyl, 2-methoxy-5-methyl-phenyl, 2-methoxy-5-fluoro-phenyl, 3-(hydroxymethyl)-phenyl, 3-trifluoromethyl-phenyl, 2-(methylcarbonylamino)-phenyl, 2-(t-butylaminosulfonyl)-phenyl, 2-(aminocarbonyl)-phenyl, 2-(methylsulfonylamino)-phenyl, 3-(methylcarbonyl)-phenyl, 3-(benzyloxycarbonylamino)-phenyl, 3-(N-(cyclohexylmethyl)-amino)-phenyl, 3-(phenylsulfonylamino)-phenyl, 2-naphthyl, 1-cyclohexenyl, 1-cyclopentenyl, 2-biphenyl, 5-pyrimidinyl, 4-pyridyl, 3-quinolinyl and 3-(6-fluoro-benzo[d]isoxazolyl);
a is an integer from 0 to 1;
R 10 is fluoro;
or a pharmaceutically acceptable salt thereof.
5. A compound as in claim 4
R 0 is hydrogen;
R 1 is hydrogen;
A 1 is selected from the group consisting of -ethyl-, -n-butyl-, -n-propyl-, 1-(R)-methyl-ethyl-, 1-n-propyl-ethyl-, 1-cyclohexyl-ethyl-, 1-(R)-cyclohexyl-ethyl-, 1-cyclohexyl-n-propyl, 1-(S)-cyclohexyl-n-propyl, 1-(R)-cyclohexyl-n-propyl, 1-(n-propyl)-n-propyl, 1-(n-propyl)-n-butyl-, 1-(R)-isopropyl-n-propyl, 1-(S)-isopropyl-n-propyl, 1-(4-chlorophenyl)-n-propyl, 1-(4-methylphenyl)-n-propyl, 1-(4-methoxyphenyl)-n-propyl, 1-(phenyl)-ethyl-, 1-(cyclohexyl-carbonyl-amino-methyl)-ethyl and 1-(N-cyclohexyl-N-methyl-amino-carbonyl-ethyl)-n-propyl;
Q 1 is selected from the group consisting of —C(O)—NH—, —C(O)—N(CH 3 )—, —C(O)—N(cyclohexyl)-, —NH—C(O)—, —NH—C(O)O—, —N(CH 3 )—C(O)O—, —NH—C(O)—NH—, —NH—C(S)—NH and —NH—SO 2 —;
R 2 is selected from the group consisting of isopropyl, n-butyl, t-butyl, 1-ethyl-n-pentyl, isopentyl, 3-n-heptyl, 4-n-heptyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentyl-methyl-, 2-methyl-cyclohexyl, 3-methoxy-cyclohexyl, phenyl, phenylethyl-, 4-(1-methyl-piperidinyl), 1-(1-(4-chlorophenyl)-cyclopentyl), 1-adamantyl and 2-adamantyl;
b is an integer from 0 to 1;
L 1 is selected from the group consisting of —C(O)— and —O—;
R 3 is selected from the group consisting of phenyl, 2-methoxyphenyl, 3-(benzyloxy-carbonyl-amino)-phenyl, 3-(N-(cyclohexyl-methyl)-amino)-phenyl and 3-(phenyl-sulfonyl-amino)-phenyl;
a is 0;
or a pharmaceutically acceptable salt thereof.
6. A compound as in claim 5
R 0 is hydrogen;
R 1 is hydrogen;
A 1 is selected from the group consisting of ethyl-, n-butyl-, 1-(R)-methyl-ethyl-, 1-n-propyl-ethyl-, 1-cyclohexyl-ethyl-, 1-(R)-cyclohexyl-ethyl-, 1-cyclohexyl-n-propyl, 1-(S)-cyclohexyl-n-propyl, 1-(n-propyl)-n-propyl, 1-(n-propyl)-n-butyl-, 1-(R)-isopropyl-n-propyl, 1-(S)-isopropyl-n-propyl, 1-(4-chlorophenyl)-n-propyl, 1-(4-methylphenyl)-n-propyl and 1-(4-methoxyphenyl)-n-propyl;
Q 1 is selected from the group consisting of —O(O)—NH—, —C(O)—N(CH 3 )—, —C(O)—N(cyclohexyl)-, —NH—C(O)—, —NH—C(O)O—, —N(CH 3 )—C(O)O—, —NH—C(O)—NH— and —NH—C(S)—NH;
R 2 is selected from the group consisting of isopropyl, t-butyl, 1-ethyl-n-pentyl, isopentyl, 3-n-heptyl, 4-n-heptyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentyl-methyl-, 2-methyl-cyclohexyl, phenyl, 4-(1-methyl-piperidinyl), 1-(1-(4-chlorophenyl)-cyclopentyl), 1-adamantyl and 2-adamantyl;
b is an integer from 0 to 1;
L 1 is —O—;
R 3 is selected from the group consisting of phenyl, 2-methoxyphenyl, 3-(benzyloxy-carbonyl-amino)-phenyl and 3-(phenyl-sulfonyl-amino)-phenyl;
a is 0;
or a pharmaceutically acceptable salt thereof.
7. A compound as in claim 6
R 0 is hydrogen;
R 1 is hydrogen;
A 1 is selected from the group consisting of ethyl-, 1-n-propyl-ethyl-, 1-cyclohexyl-ethyl-, 1-(R)-cyclohexyl-ethyl-, 1-cyclohexyl-n-propyl, 1-(5)-cyclohexyl-n-propyl, 1-(n-propyl)-n-propyl, 1-(R)-isopropyl-n-propyl and 1-(5)-isopropyl-n-propyl;
Q 1 is selected from the group consisting of —C(O)—NH—, —C(O)—N(CH 3 )— and —NH—C(O)—;
R 2 is selected from the group consisting of isopentyl, 4-n-heptyl, cyclopentyl, cyclohexyl, cyclopentyl-methyl-, 1-(1-(4-chlorophenyl)-cyclopentyl), 1-adamantyl and 2-adamantyl;
b is an integer from 0 to 1;
L 1 is —O—;
R 3 is selected from the group consisting of phenyl and 2-methoxyphenyl;
a is 0;
or a pharmaceutically acceptable salt thereof.
8. A compound as in claim 4
R 0 is hydrogen;
R 1 is hydrogen;
A 1 is selected from the group consisting of ethyl-, -n-butyl-, -n-propyl-, 1-(R)-methyl-ethyl, 1-n-propyl-ethyl, 1-(R)-n-propyl-ethyl-, 1-(n-propyl)-n-propyl-, 1-(n-propyl)-n-butyl-, 1-isopropyl-ethyl-, 1-(n-pentyl)-n-propyl-, 1-cyclohexyl-ethyl-, 1-(R)-cyclohexyl-ethyl, 1-(5)-cyclohexyl-ethyl, 1-phenyl-ethyl, 1-(4-chlorophenyl)-n-propyl-, 1-(4-methoxyphenyl)-n-propyl, 1-cyclohexyl-n-propyl-, 1-phenyl-n-propyl-, 1-(R)-isopropyl-n-propyl, 1-(S)-isopropyl-n-propyl, 1-(R)-cyclohexyl-n-propyl-, 1-(S)-(cyclohexyl)-n-propyl-, 1-(S)-(hydroxymethyl)-n-propyl-, 1-(4-tetrahydropyranyl)-n-propyl-, 1-(S)-(4-tetrahydropyranyl)-n-propyl-, 1-(4-hydroxy-cyclohexyl)-n-propyl-, 1-(S)-(4-oxo-cyclohexyl)-n-propyl, 1-(S)-(cis-4-hydroxy-cyclohexyl)-n-propyl, 1-(S)—(N-cyclohexyl-N-methyl-amino-carbonyl)-n-propyl-, 1-(N-cyclohexyl-N-methyl-amino-carbonyl-ethyl)-n-propyl- and 1-(S)-(1,4-dioxa-spiro[4.5]dec-8-yl)-n-propyl;
Q 1 is selected from the group consisting of —C(O)—NH—, —C(O)—N(CH 3 )—, —C(O)—N(ethyl)-, —C(O)—N(CH 2 CH 2 OH)—, —C(O)—N(cyclohexyl)-, —C(O)—N(hydroxyethyl)-, —C(O)—N(benzyloxy-ethyl)-, —N(CH 3 )—, —NH—C(O)—, —N(CH 3 )—C(O)—, —NH—C(O)O—, —N(CH 3 )—C(O)O—, —NH—C(O)—NH, —NH—C(S)—NH and —NH—SO 2 —;
R 2 is selected from the group consisting of carboxy-methyl, 2-cyanoethyl-, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, isopentyl, 3-n-heptyl, 4-n-heptyl, 4-carboxy-n-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentyl-methyl-, cyclopentyl-ethyl-, 1-(S)-(1-carboxy-2-hydroxy-ethyl), 1-(R)-(1-carboxy-2-hydroxy-ethyl), 1-(R)-(1-carboxy-2-t-butoxy-ethyl), 1-(S)-(1-methoxy-carbonyl-2-benzyloxy-ethyl), 1-(R)-(1-methoxy-carbonyl-2-benzyloxy-ethyl), 1-(S)-(1-carboxy-2-benzyloxy-ethyl), 1-(R)-(-carboxy-2-benzyloxy-ethyl), trans-2-methyl-cyclohexyl-, 1-(1-(4-chlorophenyl)-cyclopentyl), 3-methoxy-cyclohexyl, 4-hydroxy-cyclohexyl, 1-cis-(3-carboxy-cyclohexyl), 4-carboxy-cyclohexyl, (1)-(S)-((4R)-carboxy-cyclohexyl), (1)-(R)-((4S)-carboxy-cyclohexyl), 4-(ethoxy-carbonyl)-cyclohexyl, cis-(4-methoxy-carbonyl)-cyclohexyl, trans-(4-methoxy-carbonyl)-cyclohexyl, 1-4-oxo-cyclohexyl, 1-cis-(4-amino-carbonyl-cyclohexyl), phenyl, 2-methoxyphenyl, 2-methylphenyl, benzyl, phenylethyl-, benzhydryl, 4-(1-isopropyl)-piperidinyl, 4-(1-methyl-piperidinyl), 1-adamantyl, 2-adamantyl, 4-(tetrahydropyranyl), 5-(3-methyl-isoxazolyl)-methyl, 1,4-oxaspiro[4.5]dec-8-yl and 5-tetrazolyl-methyl;
b is an integer from 0 to 1;
L 1 is selected from the group consisting of —C(O)— and —(O)—;
R 3 is selected from the group consisting of phenyl, 2-hydroxyphenyl, 2-fluorophenyl, 2,6-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 2-methoxy-phenyl, 2-fluoro-6-methoxyphenyl, 3-hydroxymethyl-phenyl and 3-(phenyl-sulfonyl-amino)-phenyl;
a is 0;
or a pharmaceutically acceptable salt thereof.
9. A compound as in claim 8
R 0 is hydrogen;
R 1 is hydrogen;
A 1 is selected from the group consisting of -ethyl-, -n-propyl-, 1-(R)-methyl-ethyl, 1-n-propyl-ethyl, 1-(R)-n-propyl-ethyl-, 1-(n-propyl)-n-propyl-, 1-(n-propyl)-n-butyl-, 1-(n-pentyl)-n-propyl-, 1-cyclohexyl-ethyl-, 1-(R)-cyclohexyl ethyl, 1-phenyl-ethyl, 1-(4-chlorophenyl)-n-propyl-, 1-(4-methoxyphenyl)-n-propyl, 1-cyclohexyl-n-propyl-, 1-phenyl-n-propyl-, 1-(R)-isopropyl-n-propyl, 1-(5)-isopropyl-n-propyl, 1-(R)-cyclohexyl-n-propyl-, 1-(S)-(cyclohexyl)-n-propyl-, 1-(5)-hydroxymethyl)-n-propyl-, 1-(4-tetrahydropyranyl)-n-propyl-, 1-(S)-(4-tetrahydropyranyl)-n-propyl-, 1-(4-hydroxy-cyclohexyl)-n-propyl-, 1-(S)-(4-oxo-cyclohexyl)-n-propyl, 1-(S)-(cis-4-hydroxy-cyclohexyl)-n-propyl, 1-(S)—(N-cyclohexyl-N-methyl-amino-carbonyl)-n-propyl- and 1-(S)-(1,4-dioxa-spiro[4.5]dec-8-yl)-n-propyl;
Q 1 is selected from the group consisting of —C(O)—NH—, —C(O)—N(CH 3 )—, —C(O)—N(ethyl)-, —C(O)—N(CH 2 CH 20 H)—, —C(O)—N(hydroxyethyl)-, —C(O)—N(benzyloxy-ethyl)-, —N(CH 3 )—, —NH—C(O)—, —NH—C(O)O—, —N(CH 3 )—C(O)O— and —NH—C(S)—NH;
R 2 is selected from the group consisting of carboxy-methyl, isopropyl, isobutyl, t-butyl, isopentyl, 3-n-heptyl, 4-n-heptyl, 4-carboxy-n-butyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentyl-methyl-, cyclopentyl-ethyl-, 1-(S)-(1-carboxy-2-hydroxy-ethyl), 1-(R)-(1-carboxy-2-hydroxy-ethyl), 1-(R)-(1-carboxy-2-t-butoxy-ethyl), 1-(S)-(1-methoxy-carbonyl-2-benzyloxy-ethyl), 1-(R)-(1-methoxy-carbonyl-2-benzyloxy-ethyl), 1-(S)-(1-carboxy-2-benzyloxy-ethyl), trans-2-methyl-cyclohexyl-, 1-(1-(4-chlorophenyl)-cyclopentyl), 3-methoxy-cyclohexyl, 4-hydroxy-cyclohexyl, 1-cis-(3-carboxy-cyclohexyl), 4-carboxy-cyclohexyl, (1)-(S)-((4R)-carboxy-cyclohexyl), (1)-(R)-((4S)-carboxy-cyclohexyl), cis-(4-methoxy-carbonyl)-cyclohexyl, trans-(4-methoxy-carbonyl)-cyclohexyl, 1-cis-(4-amino-carbonyl-cyclohexyl), phenyl, 2-methylphenyl, phenylethyl-, 4-(1-methyl-piperidinyl), 1-adamantyl, 2-adamantyl, 4-(tetrahydropyranyl), 5-(3-methyl-isoxazolyl)-methyl and 5-tetrazolyl-methyl;
b is an integer from 0 to 1;
L 1 is selected from the group consisting of —C(O)— and —(O)—;
R 3 is selected from the group consisting of phenyl, 2-fluorophenyl, 2,6-difluorophenyl, 2-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 2-methoxy-phenyl and 2-fluoro-6-methoxyphenyl;
a is 0;
or a pharmaceutically acceptable salt thereof.
10. A compound as in claim 9
R 0 is hydrogen;
R 1 is hydrogen;
A 1 is selected from the group consisting of -ethyl-, 1-cyclohexyl-ethyl-, 1-(R)-cyclohexyl-ethyl, 1-cyclohexyl-n-propyl-, 1-(R)-isopropyl-n-propyl, 1-(S)-isopropyl-n-propyl, 1-(R)-cyclohexyl-n-propyl-, 1-(S)-(cyclohexyl)-n-propyl-, 1-(4-tetrahydropyranyl)-n-propyl-, 1-(S)-(4-tetrahydropyranyl)-n-propyl-, 1-(4-hydroxy-cyclohexyl)-n-propyl- and 1-(S)-(4-oxo-cyclohexyl)-n-propyl;
Q 1 is selected from the group consisting of —C(O)—NH—, —C(O)—N(CH 3 )—, —C(O)—N(hydroxyethyl)-, —C(O)—N(benzyloxy-ethyl)-, —C(O)—N(cyclohexyl)- and —NH—C(O)—;
R 2 is selected from the group consisting of carboxy-methyl, isobutyl, isopentyl, 1-(1-(R)-carboxy-2-hydroxy-ethyl), 1-(1-(R)-carboxy-2-t-butoxy-ethyl), 1-(1-(S)-carboxy-2-benzyloxy-ethyl), cyclopentyl, cyclohexyl, 4-carboxy-cyclohexyl, (1)-(S)-((4R)-carboxy-cyclohexyl), 1-adamantyl and 2-adamantyl;
b is an integer from 0 to 1;
L 1 is —(O)—;
R 3 is selected from the group consisting of phenyl, 2-fluorophenyl and 2-methoxy-phenyl;
a is 0;
or a pharmaceutically acceptable salt thereof.
11. A compound as in claim 4 wherein
R 0 is hydrogen; R 1 is hydrogen; A 1 is 1-(S)-cyclohexyl-n-propyl, Q 1 is selected from the group consisting of —C(O)— and —C(O)—N(cyclohexyl)-; R 2 is selected from the group consisting of 2-imidazolyl-methyl, 5-imidazolyl-methyl, 4-pyridyl-methyl, 2-carboxy-octahydroindolyl, 2R-(3R,4S,5R-tri(methoxy-carbonyl-oxy)-6R-(methyl-carbonyl-oxy-methyl)-tetrahydropyranyl)oxy-ethyl and 2R-(3S,4S,5R-trihydroxy-6R-(hydroxymethyl)-tetrahydropyranyl)oxy-ethyl; b is 1; R 3 is phenyl; and a is 0; or a pharmaceutically acceptable salt thereof.
12. A compound of formula (I)
wherein
R 0 is selected from the group consisting of hydrogen, methyl and CF 3 ;
R 1 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, trifluoromethyl, 2,2,2-trifluoroethyl, methoxy, ethoxy and methyl-carbonyl;
A 1 is selected from C 1-4 alkyl; wherein the C 1-4 alkyl is optionally substituted with one or more R X substituents;
wherein each R X is independently selected from the group consisting of hydroxy, oxo, C 1-8 alkyl, C 1-8 alkoxy, hydroxy substituted C 1-6 alkyl, amino substituted C 1-6 alkyl, cycloalkyl, cycloalkyl-C 1-4 alkyl-, biphenyl, aryl, C 1-4 aralkyl, heteroaryl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl-, spiro-heterocyclyl and —(C 1-4 alkyl) n -Q 2 -R 4 ;
wherein the R X cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl group, whether alone or as part of a substituent group is optionally substituted with a substituent selected from the group consisting of fluoro, chloro, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, —C(O)—(C 1-4 alkyoxy), hydroxy substituted C 1-4 alkyl, fluoro substituted C 1-4 alkyl, fluoro substituted C 1-4 alkoxy, 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein n is an integer from 0 to 1;
wherein Q 2 is selected from the group consisting of —O—, —S—, —C(O)—, —C(S)—, —C(O)O—, —OC(O)—, —NR G —, —NR G —C(O)—, —C(O)—NR G —, —NR G —SO 2 —, —SO 2 —NR G , —NR G —SO—, —SO—NR G , —NR G —C(O)O—, —OC(O)NR G , —O—SO 2 —NR G —, —NR G —SO 2 —O—, —NR G —C(O)—NR H , —NR G C(S)—NR H — and —NR G —SO 2 —NR H —;
wherein each R G and R H is independently selected from the group consisting of hydrogen, C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 aralkyloxy substituted C 1-4 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the independently selected R G and R H cycloalkyl aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, —SO 2 —N(R J R K ), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein each R J and R K is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
wherein R 4 is selected from the group consisting of hydrogen, C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, fluoro substituted C 1-4 alkyl, cycloalkyl, aryl, biphenyl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the R 4 cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino and phenyl;
wherein the phenyl is optionally substituted with one or more substituent independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino and —SO 2 —N(R E R F );
wherein each R E and R F is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
Q 1 is selected from the group consisting of —O—, —S—, —C(O)—, —C(S)—, —C(O)O—, —OC(O)—, —NR A —, —NR A —C(O)—, —C(O)—NR A —, —NR A —C(S)—, —C(S)—NR A —, —NR A —SO 2 —, —SO 2 NR A , —NR A —SO—, —SO—NR A , —NR A C(O)O—, —OC(O)—NR A —, —O—SO 2 NR A —, —NR A —SO 2 O—, —NR A —C(O)—NR B —, —NR A C(S)—NR B — and —NR A SO 2 —NR B —;
wherein each R A and R B is independently selected from the group consisting of hydrogen, C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 aralkyloxy substituted C 1-4 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the independently selected R A and R B cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, —SO 2 —N(R C R D ), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein each R C and R D is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
R 2 is selected from the group consisting of C 1-10 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the R 2 C 1-10 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)—C 1-4 alkyl, —C(O)—C 1-4 aralkyl, —C(O)O—C 1-4 alkyl, —C(O)O—C 1-4 aralkyl, —C 1-4 alkyl-C(O)O—C 1-4 alkyl, —C 1-4 alkyl-S—C 1-4 alkyl, —C(O)—N(R L R M ), —C 1-4 alkyl-C(O)—N(R L R M ), —NR L —C(O)C 1-4 alkyl, —SO 2 —N(R L R M ), —C 1-4 alkyl-SO 2 —N(R L R M ), C 1-6 alkyl, fluoro substituted C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, carboxy substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, phenyl, 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein the phenyl is optionally substituted with one or more substituent independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, —C(O)O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, C 1-4 alkyl, fluoro substituted C 1-4 alkyl, C 1-4 alkoxy, nitro, cyano, amino, C 1-4 alkylamino and di(C 1-4 alkyl)amino;
wherein each R L and R M is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
b is an integer from 0 to 1;
L 1 is selected from the group consisting of —O—, —S(O) 0-2 —, —NR N —, —C(O)—, —C(S)—, —C 1-4 alkyl-, -(hydroxy substituted C 1-4 alkyl) and —(C 2-4 alkenyl)-;
wherein R N is selected from the group consisting of hydrogen and C 1-4 alkyl;
R 3 is selected from the group consisting of C 2-6 alkenyl, cycloalkyl, partially unsaturated carbocyclyl, aryl, biphenyl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the R 3 cycloalkyl, partially unsaturated carbocyclyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, halogen substituted C 1-4 alkyl, cyano substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, halogen substituted C 1-4 alkoxy, nitro, cyano, —R 5 , —O—R 5 , —S—R 5 , —SO 2 —R 5 , —SO 2 —NR P —R 5 , —NR P —SO 2 —R 5 , —NH 2 , —N(R P )—R 5 , —C(O)—R 5 , —C(O)—NH 2 , —C(O)—NR P —R 5 , —NR P —C(O)—R 5 and —NR P —C(O)O—R 5 ;
wherein R 5 is selected from the group consisting of C 1-4 alkyl, aryl, C 1-4 aralkyl, partially unsaturated carbocyclyl, cycloalkyl, cycloalkyl-C 1-4 alkyl-, partially unsaturated carbocyclyl-C 1-4 alkyl-, heteroaryl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl and heterocyclyl-C 1-4 alkyl-;
wherein the R 5 aryl, C 1-4 aralkyl, partially unsaturated carbocyclyl, cycloalkyl, heteroaryl or heterocycloalkyl, whether alone or as part of a substituent group may be optionally substituted with one or more substituent independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, halogen, hydroxy, carboxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano and nitro;
wherein R P is selected from the group consisting of hydrogen, C 1-8 alkyl, hydroxy substituted C 1-4 alkyl, C 1-4 aralkyloxy substituted C 1-4 alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl-C 1-4 alkyl-, C 1-4 aralkyl, heteroaryl-C 1-4 alkyl-, heterocycloalkyl-C 1-4 alkyl- and spiro-heterocyclyl;
wherein the R P cycloalkyl, aryl, heteroaryl, heterocycloalkyl or spiro-heterocyclyl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, oxo, carboxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, nitro, cyano, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, —SO 2 —N(R S R T ), 5-tetrazolyl and 1-(1,4-dihydro-tetrazol-5-one);
wherein each R S and R T is independently selected from the group consisting of hydrogen and C 1-4 alkyl;
a is an integer from 0 to 3;
each R 10 is independently selected from the group consisting of hydroxy, halogen, C 1-4 alkyl, C 1-4 alkoxy, halogenated C 1-4 alkyl, halogenated C 1-4 alkoxy, —C(O)—NR V R W , —SO 2 —NR V R W , —C(O)—C 1-4 alkyl and —SO 2 —C 1-4 alkyl;
wherein each R V and R W is independently selected from the group consisting of hydrogen and C 1-4 alkyl; alternatively R V and R W are taken together with the N atom to which they are bound to form a 5 to 6 membered saturated, partially unsaturated or aromatic ring structure;
provided that the halogens on the halogenated C 1-4 alkyl or the halogenated C 1-4 alkoxy are selected from chloro or fluoro;
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1 .